Recruiting

Poly-L-lactic AcidClinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and Thighs

Sponsor:

Goldman, Butterwick, Fitzpatrick and Groff

Code:

NCT04830722

Conditions

Cellulite

Eligibility Criteria

Sex: Female

Age: 30 - 60

Healthy Volunteers: Accepted

Interventions

Sculptra Aesthetic

Study Details

Brief summary:

clinical trial is to assess the safety, efficacy and patient satisfaction associated with the treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic

Conditions

Cellulite

Study ID

NCT04830722

Start date

Apr 9, 2021

Status verified date

Apr, 2021

Completion date

Jun 1, 2022

Anticipated

Primary completion date

Apr 1, 2022

Anticipated

Eligibility Criteria

Sex: Female

Age: 30 - 60

Healthy Volunteers: Accepted

Inclusion Criteria:

Healthy adult females age 30 to 60
Both buttocks and/or both posterolateral thighs with a score of mild (1-5) to moderate (6-10 according to the Hexsel, Dal'Forno \& Hexsel Cellulite Severity Scale (CSS), and a laxity score using the Hexsel, Dal'Forno \& Hexsel Cellulite Severity Scale of 1 (slight) or 2 (moderate). Must be the same score on both sides of the same area (ie: if 1 on one buttock, must be 1 on the other buttock but can be a 2 on the thigh, as long as the other thigh is also a 2)
Must be willing to give and sign an informed consent form and photographic release form.
Must have had a stable body weight for at least 6 months prior to study entry.
Must be willing to maintain usual sun exposure, diet, and exercise routines for the duration of the study.
Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study.
Negative urine pregnancy test results at the time of study entry (if applicable).
For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation.
A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and/or vasectomies of partner with a documented second acceptable method of birth control, should the subject become sexually activity.
Must be willing to comply with study treatments and complete the entire course of the study.
Cellulite that improves when the skin of the buttocks or thighs are stretched or distended superiorly.

Exclusion Criteria:

Use of any of the following for the treatment of cellulite on either thigh or either buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:
Liposuction during the 12-month period prior to study treatment.
Injections (eg, mesotherapy, dermal fillers, biostimulatory fillers, clostridium collagenase histolyticum); radiofrequency device treatments; laser treatment; buttock or thigh implant treatment; cryolipolysis; or surgery (including subcision and/or powered subcision) during the 24-month period before injection of study treatment.
Any investigational treatment for cellulite on a buttock or thigh during the 12-month period before the injection of study treatment.
Endermologie or similar treatments during the 6 month period before injection of study treatment.
Massage therapy during the 3-month period before injection of study treatment.
Creams (eg, Tretinoin, Celluvera™, TriLastin®) and/or home therapies to prevent or treat cellulite during the two week period before injection of study treatment.
Subjects with scarring in treatment areas.
Has any of the following local conditions in the areas to be treated (both buttocks or both thighs):
History of lower extremity thrombosis or post-thrombosis syndrome.
Vascular disorder (eg, varicose veins)
A subject with tattoos or permanent implants in the treatment areas.
A subject with history of or the presence of any skin condition/disease in the treatment area that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis).
Subject who spray tanned or used sunless tanner in the treatment area 4 weeks prior to study treatment.
A subject with an active bacterial, fungal, or viral infection in the treatment area.
A subject with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
Any history of bleeding or coagulation disorders.
History of lidocaine sensitivity deemed by the investigator to preclude patient from enrolling in the study.
A subject planning any other cosmetic procedure to the study treatment area during the study period, other than the treatment that will be performed by the investigator.
Presence of incompletely healed wound in treatment area.
Non-Ablative laser to the treatment area in the last 3 months.
A female subject who is pregnant, nursing an infant or planning a pregnancy during the study.
Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

Study Design

Enrollment

20 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Sculptra Aesthetic Side

the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive up to two vials of Sculptra Aesthetic, for a total of 4 vials in one treatment session if 2 areas qualify.

placebo comparator: Placebo side

the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive 16 cc of bacteriostatic water, for up to 64 ccs of bacteriostatic water to match the volume injected on the active side

Interventions

Sculptra Aesthetic

One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume

Primary outcome measure

Assessing Safety [ Time Frame: 1 year ]
Assessing Efficacy [ Time Frame: 1 year ]
Assessing Patient Satisfaction [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Sherif Research Director, MD

8586571004 SMikhail@clderm.com

Leslie Aguilar, BA

18586571004 laguilar@clderm.com

Locations

Cosmetic Laser Dermatology/West Dermatology Research Center

Recruiting

San Diego, California, United States, 92121

Contacts

Leslie Aguilar, BA

858-657-1004 LAguilar@CLDerm.com

Sherif Mikhail, MD

8586571004 SMikhail@clderm.com

Principal Investigator:

Sabrina Fabi, MD

More Information

Sponsor

Goldman, Butterwick, Fitzpatrick and Groff

Last update posted

Apr 12, 2021

Last verified

Apr, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Goldman, Butterwick, Fitzpatrick and Groff on 2021-04-12.